EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma

Alpay Yeşilaltay, Dilek Muz iD, Berna Erdal iD, Türker Bilgen, Bahadır Batar, Burhan Turgut, Birol Topçu, Bahar Yılmaz, Burcu Altındağ Avcı

Pathogens · 2024

DOI: 10.3390/pathogens13010072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Alpay Yeşilaltay und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medicine, Başkent University Istanbul, Istanbul 34662, Türkiye. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Lenalidomide, Myxoma virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific and Technological Research Council of Turkey, The Scientific and Technological Research Council of Türkiye (TÜBİTAK), Deva holding ilaç AŞ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to explore the effectiveness and safety of Myxoma virus (MYXV) in MM cell lines and primary myeloma cells obtained from patients with multiple myeloma. Myeloma cells were isolated from MM patients and cultured. MYXV, lenalidomide, and bortezomib were used in MM cells. The cytotoxicity assay was investigated using WST-1. Apoptosis was assessed through flow cytometry with Annexin V/PI staining and caspase-9 concentrations using ELISA. To explore MYXV entry into MM cells, monoclonal antibodies were used. Moreover, to explore the mechanisms of MYXV entry into MM cells, we examined the level of GFP-labeled MYXV within the cells after blocking with monoclonal antibodies targeting BCMA, CD20, CD28, CD33, CD38, CD56, CD86, CD117, CD138, CD200, and CD307 in MM cells. The study demonstrated the effects of treating Myxoma virus with lenalidomide and bortezomib. The treatment resulted in reduced cell viability and increased caspase-9 expression. Only low-dose CD86 blockade showed a significant difference in MYXV entry into MM cells. The virus caused an increase in the rate of apoptosis in the cells, regardless of whether it was administered alone or in combination with drugs. The groups with the presence of the virus showed higher rates of early apoptosis. The Virus, Virus + Bortezomib, and Virus + Lenalidomide groups had significantly higher rates of early apoptosis (p < 0.001). However, the measurements of late apoptosis and necrosis showed variability. The addition of MYXV resulted in a statistically significant increase in early apoptosis in both newly diagnosed and refractory MM patients. Our results highlight that patient-based therapy should also be considered for the effective management of MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBortezomibLenalidomideMyxoma virusApoptosisOncolytic VirotherapyHumansAntineoplastic AgentsCell Line, TumorCombined Modality TherapyCell SurvivalThalidomideMale

Stichwörter der Autor:innen

bortezomiblenalidomidemultiple myelomamyxoma virusoncolytic virus

Substanzen

BortezomibLenalidomideAntineoplastic AgentsThalidomide

Autor:innen und Institutionen

  • Department of Hematology, Faculty of Medicine, Başkent University Istanbul, Istanbul 34662, Türkiye.
  • Department of Virology, Faculty of Veterinary, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
  • Department of Medical Microbiology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
  • Department of Nutrition and Dietetics, Faculty of Health Sciences, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
  • Department of Medical Biology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
  • Department of Hematology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.

ORCID-Profile: Dilek Muz, Berna Erdal

Förderung

  • Scientific and Technological Research Council of Turkey
  • The Scientific and Technological Research Council of Türkiye (TÜBİTAK)
  • Deva holding ilaç AŞ

Zitieren

APA

Yeşilaltay, A., Muz, D., Erdal, B., Bilgen, T., Batar, B., Turgut, B., Topçu, B., Yılmaz, B., & Avcı, B. A. (2024). Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma. Pathogens. https://doi.org/10.3390/pathogens13010072

Vancouver

Yeşilaltay A, Muz D, Erdal B, Bilgen T, Batar B, Turgut B, et al. Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma. Pathogens. 2024. doi:10.3390/pathogens13010072

BibTeX
@article{Yeilaltay2024,
  author = {Yeşilaltay, Alpay and Muz, Dilek and Erdal, Berna and Bilgen, Türker and Batar, Bahadır and Turgut, Burhan and Topçu, Birol and Yılmaz, Bahar and Avcı, Burcu Altındağ},
  title = {Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13010072}
}
Kostenlos starten →